176 related articles for article (PubMed ID: 26367491)
1. Sirtuin 1 promotes the growth and cisplatin resistance of endometrial carcinoma cells: a novel therapeutic target.
Asaka R; Miyamoto T; Yamada Y; Ando H; Mvunta DH; Kobara H; Shiozawa T
Lab Invest; 2015 Dec; 95(12):1363-73. PubMed ID: 26367491
[TBL] [Abstract][Full Text] [Related]
2. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2.
Peck B; Chen CY; Ho KK; Di Fruscia P; Myatt SS; Coombes RC; Fuchter MJ; Hsiao CD; Lam EW
Mol Cancer Ther; 2010 Apr; 9(4):844-55. PubMed ID: 20371709
[TBL] [Abstract][Full Text] [Related]
3. SIRT1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53.
Kim DH; Jung YJ; Lee JE; Lee AS; Kang KP; Lee S; Park SK; Han MK; Lee SY; Ramkumar KM; Sung MJ; Kim W
Am J Physiol Renal Physiol; 2011 Aug; 301(2):F427-35. PubMed ID: 21593185
[TBL] [Abstract][Full Text] [Related]
4. PGK1 facilities cisplatin chemoresistance by triggering HSP90/ERK pathway mediated DNA repair and methylation in endometrial endometrioid adenocarcinoma.
Zhou JW; Tang JJ; Sun W; Wang H
Mol Med; 2019 Mar; 25(1):11. PubMed ID: 30925862
[TBL] [Abstract][Full Text] [Related]
5. Sirtuin 1 promotes autophagy and proliferation of endometrial cancer cells by reducing acetylation level of LC3.
Huang S; Li Y; Sheng G; Meng Q; Hu Q; Gao X; Shang Z; Lv Q
Cell Biol Int; 2021 May; 45(5):1050-1059. PubMed ID: 33438275
[TBL] [Abstract][Full Text] [Related]
6. A New Synthetic Histone Deacetylase Inhibitor, MHY2256, Induces Apoptosis and Autophagy Cell Death in Endometrial Cancer Cells via p53 Acetylation.
De U; Son JY; Sachan R; Park YJ; Kang D; Yoon K; Lee BM; Kim IS; Moon HR; Kim HS
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30217020
[TBL] [Abstract][Full Text] [Related]
7. Functional and clinicopathological analysis of loss of MKK4 expression in endometrial cancer.
Ishikawa M; Nakayama K; Rahman MT; Rahman M; Katagiri A; Iida K; Miyazaki K
Oncology; 2010; 79(3-4):238-46. PubMed ID: 21372598
[TBL] [Abstract][Full Text] [Related]
8. The central Sirtuin 1/p53 pathway is essential for the orexigenic action of ghrelin.
Velásquez DA; Martínez G; Romero A; Vázquez MJ; Boit KD; Dopeso-Reyes IG; López M; Vidal A; Nogueiras R; Diéguez C
Diabetes; 2011 Apr; 60(4):1177-85. PubMed ID: 21386086
[TBL] [Abstract][Full Text] [Related]
9. IL-37bΔ1-45 suppresses the migration and invasion of endometrial cancer cells by targeting the Rac1/NF-κB/MMP2 signal pathway.
Wang X; Wei Z; Tang Z; Xue C; Yu H; Zhang D; Li Y; Liu X; Shi Y; Zhang L; Chen G; Zhou H; Wang J; Wang X
Lab Invest; 2021 Jun; 101(6):760-774. PubMed ID: 33753880
[TBL] [Abstract][Full Text] [Related]
10. Dulcitol suppresses proliferation and migration of hepatocellular carcinoma via regulating SIRT1/p53 pathway.
Lin XL; Li K; Yang Z; Chen B; Zhang T
Phytomedicine; 2020 Jan; 66():153112. PubMed ID: 31786318
[TBL] [Abstract][Full Text] [Related]
11. SIRT1 inhibition in pancreatic cancer models: contrasting effects in vitro and in vivo.
Oon CE; Strell C; Yeong KY; Östman A; Prakash J
Eur J Pharmacol; 2015 Jun; 757():59-67. PubMed ID: 25843411
[TBL] [Abstract][Full Text] [Related]
12. Lipocalin 2 Enhances Migration and Resistance against Cisplatin in Endometrial Carcinoma Cells.
Miyamoto T; Kashima H; Yamada Y; Kobara H; Asaka R; Ando H; Higuchi S; Ida K; Mvunta DH; Shiozawa T
PLoS One; 2016; 11(5):e0155220. PubMed ID: 27168162
[TBL] [Abstract][Full Text] [Related]
13. TESTIN suppresses tumor growth and invasion via manipulating cell cycle progression in endometrial carcinoma.
Gu Z; Ding G; Liang K; Zhang H; Guo G; Zhang L; Cui J
Med Sci Monit; 2014 Jun; 20():980-7. PubMed ID: 24929083
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-503 suppresses proliferation and cell-cycle progression of endometrioid endometrial cancer by negatively regulating cyclin D1.
Xu YY; Wu HJ; Ma HD; Xu LP; Huo Y; Yin LR
FEBS J; 2013 Aug; 280(16):3768-79. PubMed ID: 23731275
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer.
Nakamura M; Kyo S; Zhang B; Zhang X; Mizumoto Y; Takakura M; Maida Y; Mori N; Hashimoto M; Ohno S; Inoue M
Hum Pathol; 2010 Nov; 41(11):1516-29. PubMed ID: 20800872
[TBL] [Abstract][Full Text] [Related]
16. MLH1 enhances the sensitivity of human endometrial carcinoma cells to cisplatin by activating the MLH1/c-Abl apoptosis signaling pathway.
Li Y; Zhang S; Wang Y; Peng J; Fang F; Yang X
BMC Cancer; 2018 Dec; 18(1):1294. PubMed ID: 30594176
[TBL] [Abstract][Full Text] [Related]
17. LncRNA MST1P2/miR-133b axis affects the chemoresistance of bladder cancer to cisplatin-based therapy via Sirt1/p53 signaling.
Chen J; Li Y; Li Z; Cao L
J Biochem Mol Toxicol; 2020 Apr; 34(4):e22452. PubMed ID: 32052927
[TBL] [Abstract][Full Text] [Related]
18. Role of SIRT1 and Progesterone Resistance in Normal and Abnormal Endometrium.
Kim TH; Young SL; Sasaki T; Deaton JL; Schammel DP; Palomino WA; Jeong JW; Lessey BA
J Clin Endocrinol Metab; 2022 Feb; 107(3):788-800. PubMed ID: 34665857
[TBL] [Abstract][Full Text] [Related]
19. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
20. Assessing sirtuin expression in endometrial carcinoma and non-neoplastic endometrium.
Bartosch C; Monteiro-Reis S; Almeida-Rios D; Vieira R; Castro A; Moutinho M; Rodrigues M; Graça I; Lopes JM; Jerónimo C
Oncotarget; 2016 Jan; 7(2):1144-54. PubMed ID: 26701732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
